Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

With trial starts and a takeout, γδ therapies start coming of age 

Company data at SITC and ASH for antibodies and cell therapies directing γδ T cells to kill cancers

November 16, 2021 1:22 AM UTC

A cluster of trial starts, preliminary Phase I data and a consummated build-to-buy deal show γδ T cell-based cancer therapies are gaining momentum, with a fresh batch of data at SITC and ASH. 

The T cell subset, whose stress signal-detecting, HLA-independent TCR makes it a good fit for allogeneic cell therapies, sparked a wave of company creation about six years ago. Among the promising signals were clinical biomarker data showing high levels of tumor-infiltrating γδ T cells were predictive of favorable outcomes across a wide range of solid tumor types...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article